Mutations Counteract Abdominal Obesity and Metabolic Syndrome

RNA interface (RNAi) therapeutics company Alnylam Pharmaceuticals has made public its discovery of mutations in the INHBE gene associated with mitigating a condition that affects more than 20% of adults the world over: abdominal obesity and metabolic syndrome. Sequencing data derived from more than 360,00 individuals in U.K. Biobank provided the information that led to their discovery...